Please try another search
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company’s lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Anna Moore | 61 | 2016 | Co-Founder, Scientific Advisor & Member of Scientific Advisory Board |
Dejan Juric | - | 2021 | Member of Advisory Board |
Raghu Kalluri | - | - | Member of Advisory Board |
Oliver Steinbach | - | - | Member of Advisory Board |
G. Susan Srivatsa | - | - | Member of Advisory Board |
Keith T. Flaherty | 53 | - | Member of Advisory Board |
George Calin | - | - | Member of Advisory Board |
Raul Mostoslavsky | - | - | Member of Advisory Board |
Magda Marquet | 65 | 2021 | Independent Director |
Erik Manting | 53 | 2020 | Independent Director |
Betsabeh Madani Hermann | - | - | Member of Advisory Board |
Lubomir Nechev | - | 2021 | Member of Advisory Board |
Dmitry Samarsky | 57 | - | Member of Advisory Board |
Mehmet Yigit | - | - | Member of Advisory Board |
Jerome M. Lewis | 75 | - | Member of Advisory Board |
John B. Henneman | 62 | - | Member of Advisory Board |
Frank J. Slack | - | 2022 | Member of Advisory Board |
Philippe P. Calais | 65 | 2018 | Executive Chairman of the Board |
Thomas A. Fitzgerald | 72 | 2018 | Interim CEO, CFO, President, VP of Administration & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review